A preclinical model to assess the antigenicity of an HLA-A2 melanoma cell vaccine.

Abstract

BACKGROUND:

The authors have demonstrated that immunization with melanoma whole-cell vaccine (MCV) augments T-cell responses to melanoma and that cytotoxic T-cells (CTL) recognize allogeneic melanoma-bearing shared HLA-A antigens. A preclinical model was developed to assess CTL activation in vitro using melanoma lines as stimulators. HLA-A2 expression is predominant in melanoma patients and plays a role in HLA class I restricted CTL killing of melanomas. The authors hypothesized that a MCV consisting of allogeneic HLA-A2 melanomas may be as good as autologous melanoma MCV for HLA-A2 patients.

METHODS:

CTL were generated from peripheral blood lymphocytes of patients with HLA-A2 melanoma by stimulation with autologous melanoma, allogeneic melanoma (HLA-A2 or non-HLA-A2), or allogeneic MCV (mixed HLA-A2 and non-HLA-A2 melanomas).

RESULTS:

HLA-A2 MCV and autologous melanoma were similar and significantly better stimulators than the others. Specificity also was supported by CTL killing and mixed lymphocyte tumor reaction assays.

CONCLUSIONS:

These studies provide important information for the studying immunization of patients with HLA-A2 melanoma with an allogeneic HLA-A2 MCV in a Phase I clinical trial.

• Authors: Y Hayashi, D S Hoon, L J Foshag, M S Park, P I Terasaki, D L Morton
• Journal: Cancer (Cancer) Vol. 72 Issue 3 Pg. 750-9 (Aug 01 1993) ISSN: 0008-543X [Print] United States
• PMID: 8334627 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antigens, Neoplasm
• HLA-A2 Antigen
• Vaccines

Topics

• Antigens, Neoplasm (immunology)
• Cell Line
• Cytotoxicity, Immunologic (immunology)
• HLA-A2 Antigen (immunology)
• Humans
• Immunotherapy
• Lymphocyte Activation
• Melanoma (immunology, pathology, therapy)
• Phenotype
• T-Lymphocytes, Cytotoxic (immunology)
• Tumor Cells, Cultured
• Vaccines (immunology)